Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COP...( - Study shows significantly improve...),Health

- Study shows significantly improved bronchodilation and symptom control

with combination therapy -

NAPA, Calif., May 20 /PRNewswire/ -- A newly published study presents data demonstrating that patients with Chronic Obstructive Pulmonary Disease (COPD), including emphysema and chronic bronchitis, experienced markedly improved bronchodilation and symptom control when treated with a combination of nebulized formoterol fumarate inhalation solution (Perforomist(TM) Inhalation Solution) and tiotropium (TIO), compared to treatment with tiotropium alone. The two medications, when used adjunctively, were also well tolerated by patients over the course of the 6-week study.

"Concomitant Treatment with Nebulized Formoterol and Tiotropium in Subjects with COPD: A Placebo-Controlled Trial," published in Respiratory Medicine, assesses the efficacy and safety of the concomitant treatment of Perforomist(TM) nebulized formoterol fumarate (a long-acting beta-agonist [LABA]) and tiotropium (an anticholinergic) in 130 adults with moderate to severe COPD.

"These data provide additional insight into the additive benefit of concomitant therapy with a LABA and a long-acting anticholinergic," said Dr. Donald Tashkin, MD, FACP, FCCP, Professor of Medicine, David Geffen School of Medicine at the University of California at Los Angeles, lead author and principal investigator of the study. "When Perforomist(TM) Solution's rapid onset of action is combined with tiotropium's prolonged bronchodilation, the result appears to be a safe and effective treatment option for patients. This is great news for the millions of patients -- and their families -- who live with COPD, and who too often struggle with an insufficient number of robust treatment options."

About the Study

The study was a six-week, randomized, double-blind, placebo-controlled, parallel-group design study. COPD patients entered a 7-14 day run-in period during which subje
'/>"/>